Aktis Oncology, Inc. (NasdaqGS: AKTS)
Health Care · Biotechnology · US
$17.74
-1.44% today · -19.6% 1Y
Aktis Oncology, Inc. (NasdaqGS: AKTS) operates in the Biotechnology industry within the Health Care sector. The company is valued at $1.00B and employs 79 people.
Over the last twelve months the share price has lost 19.6%, trading between 14.72 and 34.19.
Tweenvest scores Aktis Oncology, Inc. across four factors: quality 53/100, value 52/100. Its strongest factor is quality.
AKTS price history
Not enough price history to draw a chart yet.
Key figures
- Market cap
- $1.00B
- Revenue (TTM)
- $10.06M
- P/E
- —
- EPS
- -2.77
- Dividend yield
- —
- Beta (5Y)
- —
- 52-week high
- $34.19
- 52-week low
- $14.72
- Avg volume (3M)
- —
- Shares outstanding
- 55.62M
- Employees
- 79
- Next earnings
- —
About Aktis Oncology, Inc.
Aktis Oncology, Inc. is a clinical-stage biotechnology firm dedicated to advancing targeted radiopharmaceutical therapies for cancer treatment. Their core innovation lies in a proprietary miniprotein radioconjugate platform, which enables the discovery and development of potent radiopharmaceutical therapies designed to precisely deliver tumor-killing radioisotopes. Among their pipeline candidates is Nectin-4, a miniprotein radioconjugate specifically engineered to treat locally advanced or metastatic urothelial cancer. Key programs also include AKY-1189, a radioconjugate engineered to target Nectin-4 expressing tumors across various indications such as metastatic urothelial cancer, breast cancer, non-small cell lung cancer (NSCLC), colorectal cancer, and cervical cancer. Another significant therapy, AKY-2519, is under development to deliver radioisotopes to B7-H3 (CD276) expressing tumors, addressing prostate cancer, lung cancer, and other solid tumor types. Originally incorporated as HotKnot Therapeutics, Inc., the company officially rebranded to Aktis Oncology, Inc. in April 2020. Founded in 2020, Aktis Oncology maintains its headquarters in Boston, Massachusetts.
- ISIN
- US01021M1045
- Founded
- 2020
- Listed since
- Jan 9, 2026
- Exchange
- Nasdaq Global Select
- Currency
- USD
Other Biotechnology companies
| Company | Market cap | Price | Day |
|---|---|---|---|
| Alphamab OncologySEHK: 9966 | $1.03B | HK$8.31 | -0.36% |
| Kolon TissueGene, Inc.KOSDAQ: A950160 | $1.02B | ₩16,130.00 | +2.09% |
| Cullinan Therapeutics, Inc.NasdaqGS: CGEM | $1.01B | $15.46 | -1.09% |
| Philogen S.p.A.BIT: PHIL | $1.00B | €21.85 | -1.80% |
| Basilea Pharmaceutica AGSWX: BSLN | $1.00B | CHF65.70 | -1.65% |
| Odyssey Therapeutics, Inc.NasdaqCM: ODTX | $993.11M | $18.12 | -12.57% |
| Adlai Nortye Group Ltd.NasdaqGM: ANL | $971.76M | $15.51 | +2.78% |
| LongBio Pharma (Suzhou) Co., Ltd.SEHK: 1779 | $961.56M | HK$101.70 | -10.40% |
Figures last refreshed Oct 4, 2026.